Abstract
Artemisinin-based combination therapies (ACTs) have transformed malaria treatment, boasting high efficacy and tolerability. However, emerging resistance jeopardises their long-term effectiveness. ACTs’ ability to target multiple parasite stages mitigates resistance risks, but severe malaria cases may require additional interventions. Research on combining ACTs with adjunctive therapies shows promise, but optimal regimens remain unclear. Vigilant resistance monitoring and innovative approaches are crucial to sustaining ACT efficacy. We highlight the ACTs’ benefits, limitations, and potential synergies, emphasising the urgent need for comprehensive strategies to combat malaria’s evolving challenges.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
